TY - JOUR
T1 - Further inflammatory information on metabolic syndrome by adiponectin evaluation
AU - Matsushita, Kunihiro
AU - Tamakoshi, Koji
AU - Yatsuya, Hiroshi
AU - Wada, Keiko
AU - Otsuka, Rei
AU - Takefuji, Seiko
AU - Hotta, Yo
AU - Kondo, Takahisa
AU - Murohara, Toyoaki
AU - Toyoshima, Hideaki
N1 - Funding Information:
The authors wish to express their sincere appreciation to the study participants and to the healthcare personnel of the local government office. This work was supported by Grant Nos. 17390185 (H.T.), 18590594 (K.T.), and 17790384 (H.Y.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, from the Japan Atherosclerosis Prevention Fund (JAPF), and the Aichi D.R.G. Foundation.
PY - 2008/3/14
Y1 - 2008/3/14
N2 - Background: Despite a close association of adiponectin with metabolic syndrome (MetS), its usefulness as an additional MetS factor has not been well investigated. Methods: We studied 2327 apparently healthy Japanese male office workers aged 35 to 66 years old and investigated cross-sectionally whether categorization by serum adiponectin distinguished participants' levels of high-sensitivity C-reactive protein (CRP) beyond the conventional MetS. Results: In a linear regression analysis, adiponectin was associated with CRP independently of all MetS factors (β = - 0.192, P < 0.001). Furthermore, a graded decrease in CRP level was observed with elevation of adiponectin in every stratum characterized by the presence or absence of each MetS component (trend P < 0.05 in all strata except those of decreased high-density lipoprotein cholesterol or hyperglycemia). Similarly, geometric means of CRP levels (mg/l) decreased as adiponectin increased from the lowest to the highest tertile in all strata classified by the number of MetS components, though a P value did not reach statistical significance in those with 3 MetS components (the stratum of 0 MetS component: 0.41 [95% confidence interval, 0.34-0.49], 0.32 [0.28-0.37] and 0.26 [0.23-0.30], trend P < 0.001; 1 component: 0.45 [0.39-0.52], 0.38 [0.34-0.43], and 0.32 [0.28-0.36], trend P < 0.001; 2 components: 0.58 [0.50-0.67], 0.51 [0.44-0.60], and 0.46 [0.38-0.55], trend P = 0.043; 3 components: 0.80 [0.66-0.96], 0.69 [0.55-0.87], and 0.58 [0.39-0.85], trend P = 0.139). Conclusions: Adiponectin evaluation provides additional inflammatory information on conventional MetS, supporting the potential of hypoadiponectinemia as an additional MetS component for identifying high-risk individuals for cardiovascular disease.
AB - Background: Despite a close association of adiponectin with metabolic syndrome (MetS), its usefulness as an additional MetS factor has not been well investigated. Methods: We studied 2327 apparently healthy Japanese male office workers aged 35 to 66 years old and investigated cross-sectionally whether categorization by serum adiponectin distinguished participants' levels of high-sensitivity C-reactive protein (CRP) beyond the conventional MetS. Results: In a linear regression analysis, adiponectin was associated with CRP independently of all MetS factors (β = - 0.192, P < 0.001). Furthermore, a graded decrease in CRP level was observed with elevation of adiponectin in every stratum characterized by the presence or absence of each MetS component (trend P < 0.05 in all strata except those of decreased high-density lipoprotein cholesterol or hyperglycemia). Similarly, geometric means of CRP levels (mg/l) decreased as adiponectin increased from the lowest to the highest tertile in all strata classified by the number of MetS components, though a P value did not reach statistical significance in those with 3 MetS components (the stratum of 0 MetS component: 0.41 [95% confidence interval, 0.34-0.49], 0.32 [0.28-0.37] and 0.26 [0.23-0.30], trend P < 0.001; 1 component: 0.45 [0.39-0.52], 0.38 [0.34-0.43], and 0.32 [0.28-0.36], trend P < 0.001; 2 components: 0.58 [0.50-0.67], 0.51 [0.44-0.60], and 0.46 [0.38-0.55], trend P = 0.043; 3 components: 0.80 [0.66-0.96], 0.69 [0.55-0.87], and 0.58 [0.39-0.85], trend P = 0.139). Conclusions: Adiponectin evaluation provides additional inflammatory information on conventional MetS, supporting the potential of hypoadiponectinemia as an additional MetS component for identifying high-risk individuals for cardiovascular disease.
UR - http://www.scopus.com/inward/record.url?scp=39749113166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39749113166&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2007.02.015
DO - 10.1016/j.ijcard.2007.02.015
M3 - Article
C2 - 17433469
AN - SCOPUS:39749113166
SN - 0167-5273
VL - 124
SP - 339
EP - 344
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 3
ER -